Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT01414049
Other study ID # CE10.151
Secondary ID
Status Unknown status
Phase N/A
First received August 9, 2011
Last updated March 25, 2014
Start date August 2011
Est. completion date September 2015

Study information

Verified date March 2014
Source Centre hospitalier de l'Université de Montréal (CHUM)
Contact Nicolas Noiseux, MD
Phone 514-890-8131
Email noiseuxn@videotron.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heart bypass surgery is used to increase blood flow to the heart. This surgery is usually done using a heart-lung machine (on-pump surgery) allowing the surgeon to perform the procedure on a still heart. However, this heart-lung machine causes an inflammatory response and is linked with complications such as heart injury, stroke, brain injury, kidney failure, need for blood transfusions, irregular heart rhythms and death. An effective way of counteracting the effects of the heart-lung machine is to not use the pump itself, thus performing the bypass surgery with a beating heart (off-pump surgery). However, off-pump surgery is technically more difficult, possibly associated with a decrease in graft patency. The ongoing Coronary Artery Bypass Graft Off or On Pump Revascularization Study (CORONARY), is a prospective randomized clinical trial comparing bypass surgery done with and without the pump. Worldwide, 4700 patients will be included and followed up for 5 years. The proposed research project, The Patency AssessmenT of grafts pErformed iN CORONARY (PATENCY-CORONARY), is a prospective clinical trial for the evaluation of patency (or "openness") of the bypass grafts that will enrol 1200 consecutive CORONARY patients reaching their one year follow-up. Patients will undergo a non-invasive scan using X-rays to safely and quickly evaluate graft patency. The PATENCY-CORONARY trial will determine if off-pump surgery is associated with decreased graft patency at 1-year post-surgery compared to on-pump surgery when performed by skilled surgeons in different clinical settings, whether decreased graft patency is associated with adverse short and long-term outcomes, and explore other risk factors associated with decreased graft patency.


Description:

Background: As Coronary Artery Bypass Grafting (CABG) aims to restore adequate blood supply to the ischemic heart, the success of the operation should depend mainly on the patency of the bypass grafts. Graft failure has consequences similar to those of native coronary artery disease: recurrent angina, myocardial infarct (MI), additional revascularization procedures, and premature death. CABG is generally performed using cardiopulmonary bypass (CPB) with cardioplegic arrest allowing the surgeon to complete the delicate coronary anastomoses on a still heart in a bloodless field. Off-pump CABG surgery using specially designed heart stabilizer systems has been proposed as a less invasive approach to CABG avoiding the CPB circuit itself. The benefits of off-pump CABG compared with conventional on-pump CABG are still intensively debated. Multislice spiral computed tomography angiography (CTA) represents a non-invasive method as compared to conventional coronary angiography allowing a comprehensive and objective imaging of bypass grafts and native coronaries with elevated diagnostic accuracy.

Rationale: CORONARY trial (NCT00463294) is a large, international, prospective, CIHR-funded, randomized controlled trial assessing both the short and long-term clinical outcomes of 4,700 patients undergoing on-pump or off-pump CABG. However, angiographic evaluation of coronary graft patency was not intended in CORONARY.

Objectives: PATENCY-CORONARY is a new prospective trial of a consecutive subset of 1,200 CORONARY patients reaching their one-year follow-up who will undergo graft patency assessment using CTA and 3D reconstructions. This trial will determine whether off-pump compared to on-pump CABG surgery is associated with lower CABG patency when performed by experienced surgeons and if there is an association between graft failure assessed by CTA, and the occurrence of CORONARY primary outcomes (composite of death, angina, MI, stroke, renal failure and new coronary revascularization [CABG or PCI]).

Primary outcome: CABG patency index (i.e. the percentage of patent [non-occluded] distal anastomoses out of the total number of distal anastomoses for all patients) at 1 year after CABG surgery by experienced surgeons; Secondary outcomes: 1) graft lesion severity on a 3-point scale at 1 year (mimicking the FitzGibbon grading ABO); and 2) percentage of patients with at least one occluded bypass graft at 1 year; Tertiary outcome: correlation between CTA findings (compromised grafts) with CORONARY primary outcomes(composite of death, angina, MI, stroke, renal failure and new coronary revascularization [CABG or PCI]), at one and five-year of follow-up post-CABG.

Methods: All CORONARY patients reaching their one-year follow-up will be included consecutively in the PATENCY-CORONARY trial until the target of 1,200 CTA is reached and reasons for exclusion will be noted prospectively to prevent selection bias. Amount of contrast agent used, radiation dose and potential morbidities during this imaging procedure will be recorded. Each CTA examination will be assessed by two experienced and blinded radiologists and each graft will be classified according to conduit type and portions: body of the graft, anastomoses and the distal native coronary bed. In addition of PATENCY-CORONARY outcome analyses, patients undergoing CTA will be compared to excluded patients (no CTA) and the overall cohort of patients.


Recruitment information / eligibility

Status Unknown status
Enrollment 1200
Est. completion date September 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

•All CORONARY (NCT00463294) patients reaching their one-year follow-up (9-24 months) will be included consecutively in the PATENCY-CORONARY trial.

Exclusion Criteria:

- Has a history of severe hypersensitivity to iodinated contrast agents;

- Has known or suspected for pheochromocytoma;

- Has severe renal impairment (estimated glomerular filtration rate, eGFR <35 mL/min/1.73 m2). Patients with eGFR 35-50 mL/min/1.73 m2 will be treated with hydratation and N-acetylcysteine (Mucomyst®) as per local protocol for contrast administration;

- Has rapid atrial fibrillation or any other cardiac rhythm that precludes reliable ECG triggering;

- Has severe congestive heart failure, New York Heart Association (NYHA) Class IV;

- Is a pregnant or lactating female.

Study Design


Related Conditions & MeSH terms

  • Complications Due to Coronary Artery Bypass Graft
  • Graft Failure

Intervention

Procedure:
On-pump CABG
Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
Off-pump CABG
CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.

Locations

Country Name City State
Canada Libin Cardiovascular Institute of Alberta Calgary Alberta
Canada Population Health Research Institute Hamilton Ontario
Canada Centre Hospitalier University de Montreal Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
Centre hospitalier de l'Université de Montréal (CHUM) Centre de Recherche du Centre Hospitalier de l'Université de Montréal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary CABG Patency index CABG patency index (i.e. the percentage of patent [non-occluded] distal anastomoses out of the total number of distal anastomoses for all patients) at 1 year after CABG surgery by experienced surgeons. 12 months
Secondary Graft lesion severity Graft lesion severity on a 3-point scale at 1 year (mimicking the FitzGibbon grading ABO). 12 months
Secondary Patients with at least one occluded graft Percentage of patients with at least one occluded bypass graft at 1 year. 12 months
Secondary Grafts compromised and clinical outcomes Correlation between CTA findings (compromised grafts) with clinical primary outcomes of CORONARY trial (Myocardial infarct, Stroke, death), at one and five-year of follow-up post-CABG. 12 months and 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT03948529 - RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation Phase 2
Completed NCT03663036 - Arthroscopic Superior Capsular Reconstruction With Fascia Lata Autograft - Survivorship of the Autograft Analysis N/A
Not yet recruiting NCT05855707 - Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis Phase 1
Recruiting NCT04967391 - Tumescence in HNC Skin Graft Reconstruction Phase 3
Recruiting NCT02061462 - EVLP to Evaluate the Eligibility for Transplantation of DCD-Lungs Phase 1
Completed NCT01970605 - Silver Graft All Comers Registry
Terminated NCT01564095 - TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion Phase 2/Phase 3
Terminated NCT00208884 - Terminal Graft Failure N/A
Recruiting NCT04779957 - Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy Phase 2
Terminated NCT04494061 - A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
Terminated NCT04731298 - Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT. Phase 2
Completed NCT01848249 - Deceased Donor Biomarkers and Recipient Outcomes
Active, not recruiting NCT02556879 - Immunization Anti HLA in the Liver Transplant Recipients (DSATH) N/A
No longer available NCT02026934 - CliniMACS® CD34+ Reagent System for Expanded Access Use N/A
Recruiting NCT00472329 - Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant Phase 2
Completed NCT04542954 - Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
Recruiting NCT03717545 - Second Transplantation for Graft Failure N/A
Recruiting NCT03019809 - A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Phase 2
Recruiting NCT01631058 - Renal Transplantation in the Elderly - nEverOld Study Phase 4
Completed NCT06340607 - Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients

External Links